The US is the bigger Asthma & COPD Drugs market: $20.8 Bn against $4 Bn in 2023, about 5.2 times as large.
China grows faster: 5.5% a year, against 2%. The gap still grows from $16.8 Bn to $18.5 Bn by 2033.
Clinical research: 328 active trials in the US, 175 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $20.8 Bn | $4 Bn |
| Market size, 2033 projected | $25.3 Bn | $6.8 Bn |
| Growth a year (CAGR) | 2% | 5.5% |
| Money added, 2023–2033 | $4.6 Bn | $2.8 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $61 | $2.83 |
| Active clinical trials | 328 | 175 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Asthma & COPD Drugs, US or China?
The US is the bigger Asthma & COPD Drugs market: $20.8 Bn against $4 Bn in 2023, about 5.2 times as large.
Which grows faster in Asthma & COPD Drugs, US or China?
China grows faster: 5.5% a year, against 2%. The gap still grows from $16.8 Bn to $18.5 Bn by 2033.
More Asthma & COPD Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.